Department of Cardiology, Copenhagen University Hospital Gentofte, Denmark.
Int J Cardiol. 2013 Sep 10;167(6):2904-11. doi: 10.1016/j.ijcard.2012.07.018. Epub 2012 Aug 19.
The inflammatory biomarkers soluble urokinase plasminogen activator receptor (suPAR) and C-reactive protein (CRP) independently predict cardiovascular disease (CVD). The prognostic implications of suPAR and CRP combined with Framingham Risk Score (FRS) have not been determined.
From 1993 to 1994, baseline levels of suPAR and CRP were obtained from 2315 generally healthy Danish individuals (mean [SD] age: 53.9 [10.6] years) who were followed for the composite outcome of ischemic heart disease, stroke and CVD mortality.
During a median follow-up of 12.7 years, 302 events were recorded. After adjusting for FRS, women with suPAR levels in the highest tertile had a 1.74-fold (95% confidence interval [CI]: 1.08-2.81, p=0.027) and men a 2.09-fold (95% CI: 1.37-3.18, p<0.001) increase in risk compared to the lowest tertile. Including suPAR and CRP together resulted in stronger risk prediction with a 3.30-fold (95% CI: 1.36-7.99, p<0.01) increase for women and a 3.53-fold (1.78-7.02, p<0.001) increase for men when both biomarkers were in the highest compared to the lowest tertile. The combined extreme tertiles of suPAR and CRP reallocated individuals predicted to an intermediate 10-year risk of CVD of 10-20% based on FRS, to low (<10%) or high (>20%) risk categories, respectively. This was reflected in a significant improvement of C statistics for men (p=0.034) and borderline significant for women (p=0.054), while the integrated discrimination improvement was highly significant (P≤0.001) for both genders.
suPAR provides prognostic information of CVD risk beyond FRS and improves risk prediction substantially when combined with CRP in this setting.
炎症生物标志物可溶性尿激酶型纤溶酶原激活物受体 (suPAR) 和 C 反应蛋白 (CRP) 均可独立预测心血管疾病 (CVD)。尚未确定 suPAR 和 CRP 与 Framingham 风险评分 (FRS) 联合的预后意义。
1993 年至 1994 年,从 2315 名一般健康的丹麦个体(平均[标准差]年龄:53.9[10.6]岁)中获得了基线 suPAR 和 CRP 水平,这些个体随访了缺血性心脏病、中风和 CVD 死亡率的复合结局。
中位随访 12.7 年后,记录了 302 例事件。在调整 FRS 后,suPAR 水平处于最高三分位的女性发生风险较最低三分位增加 1.74 倍(95%置信区间[CI]:1.08-2.81,p=0.027),男性增加 2.09 倍(95% CI:1.37-3.18,p<0.001)。将 suPAR 和 CRP 一起纳入可提高风险预测能力,与最低三分位相比,女性的风险增加 3.30 倍(95% CI:1.36-7.99,p<0.01),男性的风险增加 3.53 倍(1.78-7.02,p<0.001),当两个生物标志物均处于最高三分位时。与 FRS 预测的 10-20%的中等 10 年 CVD 风险相比,suPAR 和 CRP 的联合极端三分位将个体重新分配到低(<10%)或高(>20%)风险类别,这反映在男性的 C 统计量显著提高(p=0.034)和女性边缘显著提高(p=0.054),而在两性中综合区分改善均具有统计学意义(P≤0.001)。
suPAR 提供了 CVD 风险的预后信息,超出了 FRS 的范围,并且当与 CRP 联合使用时,可大大提高风险预测能力。